References

Contemporary outcomes of anemia in US patients with chronic kidney disease

10.1093/ckj/sfab195 · 2022 · External reference

Treatment of anemia in kidney disease: beyond erythropoietin

10.1016/j.ekir.2021.05.028 · 2021 · External reference

Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment

10.1681/asn.2019020213 · 2020 · External reference

KDIGO 2026 clinical practice guideline for the Management of Anemia in chronic kidney disease (CKD)

10.1016/j.kint.2025.06.006 · 2026 · External reference

Anaemia in CKD—treatment standard

10.1093/ndt/gfad250 · 2024 · External reference

Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

10.1016/j.kint.2023.05.009 · 2023 · External reference

Cardiac and kidney adverse effects of HIF prolyl‐hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta‐analysis

10.1053/j.ajkd.2022.09.014 · 2023 · External reference

Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors

10.1111/nep.13835 · 2021 · External reference

The PRISMA extension statement for reporting of systematic reviews incorporating network meta‐analyses of health care interventions: checklist and explanations

10.7326/m14-2385 · 2015 · External reference

Unresolved reference

2024 · External reference

CINeMA: an approach for assessing confidence in the results of a network meta‐analysis

10.1371/journal.pmed.1003082 · 2020 · External reference

Unresolved reference

External reference

Bias in meta‐analysis detected by a simple, graphical test

10.1136/bmj.315.7109.629 · 1997 · External reference

Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis‐stimulating agents: a randomized, open‐label, phase 3 study

10.1159/000518072 · 2021 · External reference

Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study

10.1681/asn.2020081150 · 2021 · External reference

Erythropoiesis‐stimulating agents for preventing acute kidney injury

2024 · External reference

Evolving strategies in the treatment of Anaemia in chronic kidney disease: the HIF‐prolyl hydroxylase inhibitors

10.1007/s40265-022-01783-3 · 2022 · External reference

Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease

2022 · External reference

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials

10.1039/c7sc02103h · 2017 · External reference

Anemia and iron deficiency in heart failure: current concepts and emerging therapies

10.1161/circulationaha.118.030099 · 2018 · External reference

Risk factors for heart failure in patients with chronic kidney disease: the CRIC (chronic renal insufficiency cohort) study

10.1161/jaha.116.005336 · 2017 · External reference

Treatment of anemia with darbepoetin alfa in systolic heart failure

10.1056/nejmoa1214865 · 2013 · External reference

Roxadustat treatment of chronic kidney disease‐associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double‐blind, placebo‐controlled trial

10.1007/s12325-019-00943-4 · 2019 · External reference

Phase 3 study of Roxadustat to treat anemia in non–dialysis‐Dependant CKD

10.1016/j.ekir.2021.04.003 · 2021 · External reference

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open‐label, active‐controlled study (DOLOMITES)

10.1093/ndt/gfab191 · 2021 · External reference

Randomized placebo‐controlled dose‐ranging and pharmacodynamics study of roxadustat (FG‐4592) to treat anemia in nondialysis‐dependent chronic kidney disease (NDD‐CKD) patients

10.1093/ndt/gfv302 · 2015 · External reference

A novel hypoxia‐inducible factor‐prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28‐day, phase 2A randomized trial

10.1053/j.ajkd.2015.11.021 · 2016 · External reference

A randomized trial of Roxadustat in anemia of kidney failure: SIERRAS study

10.1016/j.ekir.2021.04.007 · 2021 · External reference

Roxadustat treatment for anemia in patients undergoing long‐term dialysis

10.1056/nejmoa1901713 · 2019 · External reference

Roxadustat for anemia in patients with kidney disease not receiving dialysis

10.1056/nejmoa1813599 · 2019 · External reference

Vadadustat in patients with anemia and non‐dialysis‐dependent CKD

10.1056/nejmoa2035938 · 2021 · External reference

Roxadustat for CKD‐related anemia in non‐dialysis patients

10.1016/j.ekir.2020.11.034 · 2021 · External reference

Roxadustat for the maintenance treatment of anemia in patients with end‐stage kidney disease on stable dialysis: a European phase 3, randomized, open‐label, active‐controlled study (PYRENEES)

10.1007/s12325-021-01904-6 · 2021 · External reference

Safety and efficacy of Vadadustat for anemia in patients undergoing dialysis

10.1056/nejmoa2025956 · 2021 · External reference

Roxadustat versus Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study

10.1681/asn.2020111638 · 2022 · External reference

Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial

10.1093/ndt/gfw418 · 2017 · External reference

Four‐week studies of Oral hypoxia‐inducible factor‐prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia

10.1681/asn.2014111139 · 2016 · External reference

Daprodustat for anemia: a 24‐week, open‐label, randomized controlled trial in participants with chronic kidney disease

10.1093/ckj/sfy013 · 2019 · External reference

The ASCEND‐NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non‐dialysis chronic kidney disease

10.1016/j.kint.2023.02.019 · 2023 · External reference

Effects of Molidustat in the treatment of anemia in CKD

10.2215/cjn.02510218 · 2019 · External reference

Clinical trial of Vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease

10.1159/000464476 · 2017 · External reference

Daprodustat for anemia: a 24‐week, open‐label, randomized controlled trial in participants on hemodialysis

10.1093/ckj/sfy014 · 2019 · External reference

Unresolved reference

External reference

Vadadustat, an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients

10.1093/ndt/gfaa060 · 2020 · External reference

Daprodustat compared with Epoetin Beta Pegol for anemia in Japanese patients not on dialysis: a 52‐week randomized open‐label phase 3 trial

10.1159/000513103 · 2021 · External reference

Phase 3 randomized study comparing Vadadustat with Darbepoetin Alfa for anemia in Japanese patients with nondialysis‐dependent CKD

10.1681/asn.2020091311 · 2021 · External reference

Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis‐dependent chronic kidney disease

10.1016/j.kint.2016.07.019 · 2016 · External reference

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

10.1056/nejmoa0907845 · 2009 · External reference

Roxadustat for anemia in patients with end‐stage renal disease incident to dialysis

10.1093/ndt/gfab051 · 2021 · External reference

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double‐blind, placebo‐controlled study (ALPS)

10.1093/ndt/gfab057 · 2021 · External reference

Daprodustat for the treatment of anemia in patients undergoing dialysis

10.1056/nejmoa2113379 · 2021 · External reference

Daprodustat for the treatment of anemia in patients not undergoing dialysis

10.1056/nejmoa2113380 · 2021 · External reference

Efficacy and safety of Daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial

10.1001/jamainternmed.2022.0605 · 2022 · External reference

Vadadustat three times weekly in patients with anemia due to dialysis‐dependent CKD

10.1053/j.ajkd.2024.09.006 · 2025 · External reference

Efficacy and safety of Molidustat for anemia in ESA‐naive nondialysis patients: a randomized, phase 3 trial

10.1159/000518071 · 2021 · External reference